News2019-09-25T15:29:32-07:00

News

7September 2021

Immunotherapy Resistance in Non-Small Cell Lung Cancer: A Rubik’s Cube to Assemble

Research, Treatments|

*July 2021* Note: Although the use of immunotherapy can be questionable in EGFR+ lung cancer, resistance to immunotherapy might be of interest anyway. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and is usually

7September 2021

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

Research, Treatments|

*May 2021* Note: Is further evaluation of the combination warranted for patients with locally advanced or metastatic T790M-negative, EGFR-positive NSCLC? The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung

7September 2021

Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Out

Research, Treatments|

*July 2021* Note  Should a VEGF inhibitor (bevacizumab/Avastin) be combined with osimertinib or not? The role of osimertinib combinations as second-line treatment for advanced non-small cell lung cancer (NSCLC) is still unclear, according to researchers. Osimertinib is a standard first-line treatment

7September 2021

Efficacy and Safety of Patritumab Deruxtecan in EGFR Mutated NSCLC Resistant to EGFR TKI Therapy

Research, Treatments|

*July 2021* Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a fully human monoclonal antibody to HER3 attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker, achieved clinically meaningful, durable efficacy in a phase I

7September 2021

Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC

Research, Treatments|

*July 2021* Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had progressed on osimertinib, according to a cohort analysis of the

7September 2021

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

Research, Treatments|

*July 2021* As research efforts prevail with encouraging therapies designed to overcome resistance to EGFR-directed therapies for patients with advanced non–small cell lung cancer (NSCLC), Sukhmani K. Padda, MD, noted that hope indeed exists for this patient populations. “There

7September 2021

Optimizing Osimertinib Treatment Strategies Relies on Identification of Resistance

Research, Treatments|

*July 2021* Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) in the first line setting are the key to unlocking the next wave of success in treating lung cancer, according to Jonathan

6September 2021

Experts Break Down Exciting Breakthroughs in NSCLC

Research, Treatments|

*June 2021* Treatment advances for patients with non–small cell lung cancer (NSCLC) who harbor HER2, EGFR, KRAS, and MET mutations have generated significant excitement and set the stage for further research aimed at generating better tolerated, more effective, and optimally sequenced treatments. Nicholas C.

6September 2021

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

Research, Treatments|

*ASCO 2021* Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation tyrosine kinase inhibitor, in both treatment-naïve and osimertinib (osi)-relapsed patients (pts) with EGFRm NSCLC (Cho Ann Oncol 2020;31:S813). We

6September 2021

Clinical Challenge: Optimal Therapies for Rare EGFR Mutations in NSCLC

Research, Treatments|

*June 2021* — Patients harboring these uncommon mutations may need "special selection of EGFR TKIs" EGFR mutations in non-small cell lung cancer (NSCLC) were first pinpointed in 2004. These mighty mutations have emerged as the strongest predictor of response to EGFR tyrosine kinase

6September 2021

Randomized phase III trial of aumolertinib vs gefitinib as 1st line treatment for EGFR exon 19 del or L858R mutations

Research, Treatments|

*ASCO 2021* Note: Could this become a less-expensive alternative to osimertinib? Background: Au is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations.

6September 2021

Dr. Spira on the Updated Results of the CHRYSALIS Trial in EGFR-Mutant NSCLC

Research, Treatments|

*June 2021* Note: The CHRYSALIS Trial, involves a combination of amivantamab and lazertinib in patients with Tagrisso-relapsed and chemo naïve cancer. Alexander Spira, MD, PhD, FACP, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and

6September 2021

Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC

Research, Treatments|

*April 2021* Note: This trial indicates that this might be a good treatment for post-Tagrisso progression, even in heavily pre-treated patients. Dr. Pasi Jänne shares updated phase 1 data on the antibody–drug conjugate patritumab deruxtecan in advanced EGFR-mutated non-small-cell

24June 2021

New EGFR Resisters Multi-Year Research Partnership with Lung Cancer Research Foundation (LCRF)

Advocacy, Funding|

*June 2021* The EGFR Resisters is thrilled to announce a new multi-year research partnership with Lung Cancer Research Foundation (LCRF)!  LCRF is a large non-profit lung cancer advocacy organization based in New York whose mission is to improve lung

24June 2021

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

Research, Treatments|

*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symptomatic response to systemic pemetrexed

21June 2021

Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib

Research, Treatments|

*April 2021* MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR revealed promising results in recent clinical trials. Nevertheless, acquired resistance mechanisms to combined EGFR and MET inhibition are poorly

21June 2021

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

Research, Treatments|

*May 2021* The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation after progression on an EGFR tyrosine

21June 2021

Ask the Experts: Progression. Now What? Necessary Testing, Common Mechanisms of EGFR-Dependent Resistance, and Possible Treatment Strategies

Research, Treatments|

*June 2021* This webinar focuses on necessary testing, common mechanisms of EGFR-dependent resistance, and possible treatment strategies. Dr. Josh Bauml and Dr. Melina Marmarelis, both from the University of Pennsylvania provide their expertise. Watch it here.

21June 2021

FDA Grants Priority Review to Mobocertinib for Advanced EGFR Exon 20–Mutant NSCLC

Research, Treatments|

*April 2021* The FDA has granted a priority review designation to a new drug application (NDA) for mobocertinib (TAK-788) for the treatment of adult patients with EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer (NSCLC), as detected via an

20June 2021

Osimertinib Combos Under Evaluation to Improve Outcomes, Combat Resistance in EGFR+ NSCLC

Research, Treatments|

*April 2021* Jyoti D. Patel, MD, discusses how the FDA approval of adjuvant osimertinib has impacted the treatment of patients with EGFR-positive NSCLC, efforts being made to overcome resistance to the third-generation EGFR TKI, and other approaches under exploration

20June 2021

Overcoming therapy resistance in EGFR-mutant lung cancer

Research, Treatments|

*April 2021* Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor response rates, all patients eventually progress

20June 2021

Telisotuzumab Vedotin Demonstrates Efficacy and Tolerability in Previously Treated c-MET+ NSCLC

Research, Treatments|

*April 2021* Single-agent telisotuzumab vedotin (teliso-v; ABBV-399) induced an encouraging objective response rate (ORR) with a tolerable safety profile in patients with previously treated non–small cell lung cancer (NSCLC) who were c-MET positive, according to data from a phase

19June 2021

Patritumab Deruxtecan Under Exploration in Phase 2 HERTHENA-Lung01 Trial for EGFR+ NSCLC

Research, Treatments|

*April 2021* The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy. Read more.

19June 2021

Exploring EGFR Mutations in Lung Cancer: Key Diagnostic & Management Strategies

Research, Treatments|

*April 2021* Lung cancer expert Dr. Pasi Janne, a professor of medicine at Harvard Medical School and a translational thoracic medical oncologist at the Dana-Farber Cancer Institute, speaks about EGFR treatments including post-progression following osimertinib. This is a very informative podcast

19June 2021

Ask the Experts: Progression and Resistance “I Have Another Oncogene Driver! What are the Implications of This?”

Research, Treatments|

*March 2021* This webinar focuses on the development of new oncogene drivers upon progression and resistance. Dr. Zofia Piotrowska and Dr. Catherine Meador, both from Massachusetts General in Boston, provide their expertise. Watch the video here.

19June 2021

EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award

Research, Treatments|

*February 2021* WASHINGTON, Feb. 19, 2021 /PRNewswire/ -- Patient group EGFR Resisters and LUNGevity Foundation today announced the 2021 recipients of the first EGFR Resisters/LUNGevity Lung Cancer Research Award. This award program, driven by EGFR Resisters—a grassroots patient-led group that has 2,500+

22March 2021

Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC

Research, Treatments|

*February 2021* In EGFR-mutant non–small cell lung cancer (NSCLC) and brain metastases, oral osimertinib (Tagrisso) achieved rapid, high, and uniform brain exposure which was followed reduction in total brain metastases volume, according to results from the phase 1 ODIN-BM

22March 2021

EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase

Research, Treatments|

*February 2021* Highlights from Dr. Collin Blakely's presentation: EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase at the 2021 Targeted Therapies Conference: EGFR C797S is the predominant on-target resistance mutation Osimertinib + gefitinib prevents acquired second-site EGFR resistance mutations

22March 2021

New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward

Research, Treatments|

*January 2021* The utility of EGFR TKIs in select subgroups of patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), as well as their role in the adjuvant setting, are beginning to be teased out, explained Timothy F. Burns, MD,

22March 2021

TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer, But May Be Eclipsed by ADCs

Research, Treatments|

*January 2021* Poziotinib, mobocertinib (TAK-788), and fam-trastuzumab deruxtecan-nxki (Enhertu) are among some of the agents that have positioned HER2 as a must-test alteration in newly diagnosed advanced lung cancer, explained Lecia V. Sequist, MD, MPH, who added that the specificity of

22March 2021

Navigating Nuances in Early and Metastatic Lung Cancer Treatment

Research, Treatments|

*January 2021* The treatment paradigms of early-stage and metastatic lung cancer have expanded significantly in recent years with the addition of immunotherapy and targeted therapy options, said Brendon Stiles, MD, who added that challenges regarding screening, molecular testing, and

22March 2021

Chemoimmunotherapy Continues to Display Survival Benefits in Small Cell Lung Cancer

Research, Treatments|

*January 2021* Atezolizumab (Tecentriq), durvalumab (Imfinzi), pembrolizumab (Keytruda), and nivolumab (Opdivo) have demonstrated improved survival in combination with etoposide and platinum (EP) in untreated extensive-stage small cell lung cancer (ES-SCLC), cementing checkpoint inhibition plus chemotherapy as a frontline standard,

17March 2021

Osimertinib/Bevacizumab Improves ORR, But Fails to Prolong PFS in EGFR T790M+ NSCLC

Research, Treatments|

*January 2021* The combination of osimertinib (Tagrisso) plus bevacizumab (Avastin) failed to result in a statistically significant improvement in progression-free survival (PFS) versus osimertinib alone in patients with advanced lung adenocarcinoma that harbored an EGFR T790M mutation, according to findings from

17March 2021

Options for Patients with NSCLC That Has Progressed After Osimertinib

Research, Treatments|

*January 2021* Osimertinib (Tagrisso) has a strong foothold as first-line therapy for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but resistance to the third-generation EGFR tyrosine kinase inhibitor is a major stumbling block. "Understanding osimertinib resistance mechanisms

6March 2021

Multicenter Analysis of Mechanisms of Resistance to Osimertinib in EGFR Mutated NSCLC: An ATOMIC Registry Study

Research, Treatments|

*January 2021* The ATOMIC consortium is a group of thoracic oncologists from North America. They received funding from AstraZeneca to build a registry of patients with EGFR+ NSCLC. The registry contains all treatments given, molecular tests performed, and radiologic

6March 2021

Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC

Research, Treatments|

*January 2021* Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the

6March 2021

Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions

Advocacy|

*January 2021* Jill Feldman, co-founder of the EGFR Resisters, presented on Diversifying Clinical Trial Inclusion Criteria: Currrent Challenges and Potential Solutions to help ensure every decision, starting at concept is looked at through a health equity lens. Creating clinical trials

31January 2021

Perception of Palliative Care and Prognostic Awareness of Lung Cancer Treatment in an Oncogene-Driven Lung Cancer Community

Research, Treatments|

*January 2021* Project PRIORITY is a patient-founded and patient-driven research partnership between the EGFR Resisters and LUNGevity Foundation. This specific part of the study was presented as a poster in WCLC 2020 and focuses on palliative care and prognostic

21January 2021

Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy

Research, Treatments|

*December 2020* Robust data on the outcome of MET-aberrant non-small cell lung cancer (NSCLC) with non-targeted therapies is limited, especially in consideration of the heterogeneity of MET-amplified tumors. METex14, METamp GCN≥10, and METamp GCN<10 represent subgroups of MET-dysregulated NSCLC with distinct molecular and clinical

21January 2021

Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine

Research, Treatments|

*December 2020* Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer (NSCLC), redirecting attention toward advances in biomarker testing

21January 2021

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Research, Treatments|

*November 2020* Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, efficiently penetrates the blood-brain barrier. This study explored whether treatment with osimertinib leads to improved overall survival (OS) for patients with EGFR-mutated NSCLC with leptomeningeal metastases (LM) compared with those

21January 2021

Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC

Research, Treatments|

*December 2020* Because no standard approaches exist for patients with EGFR-mutated non–small cell lung cancer (NSCLC) who progress on standard frontline osimertinib (Tagrisso), repeat genomic testing should be done to identify potential resistance mechanisms that can help guide the next

6January 2021

New Clinical Trial: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Research, Treatments|

*November 2020* This new clinical trial is for those people whose EGFR lung cancer has transformed to small cell lung cancer.This trial covers travel expenses as well. Any questions can be directed to Dr. Anish Thomas at: Anish.Thomas@nci.gov. (In

6January 2021

Neratinib Shows Early Activity in EGFR Exon 18–Mutated, Metastatic NSCLC

Research, Treatments|

*November 2020* Neratinib (Nerlynx) showcased early activity when used in patients with metastatic non–small cell lung cancer (NSCLC) who harbor EGFR exon 18 mutations, according to interim data from the phase 2 SUMMIT trial.1 Results demonstrated that among 10 evaluable patients

6January 2021

Inhibitors of MET, RET, and TRK Now Enjoy Standard of Care Status in Lung Cancer

Research, Treatments|

*November 2020* In the treatment of lung tumors, alterations in MET as well as gene fusions in RET and NTRK are now established actionable drivers of oncogenesis, made evident by the availability of FDA-approved and guidelines-indicated therapies for each

6January 2021

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC

Research, Treatments|

*November 2020* Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor (EGFR) oncogene addicted tumor. In these patients, despite the clear benefits

6January 2021

Growth of Targeted Therapy Requires More Nuanced Treatment Considerations in NSCLC

Research, Treatments|

*November 2020* The role of targeted therapy is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer (NSCLC), said D. Ross Camidge, MD, PhD, who added that among multiple therapeutic options for common aberrations, such

6January 2021

Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer

Uncategorized|

*November 2020* Communities sharing particular types of the disease are helping steer research towards better therapies. Patient advocates often want immediate results but this can be at odds with the slow pace of scientific investigation. Yet clinicians and scientists

6January 2021

New study shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer

Research, Treatments|

*September 2020* New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell

6January 2021

Identifying, Treating Resistance to TKIs Are Next Step in EGFR+ NSCLC

Research, Treatments|

*October 2020* Identifying how to best treat patients who develop resistance to EGFR-targeted therapy, especially frontline osimertinib (Tagrisso), is part of the next chapter of research in this molecularly driven non–small cell lung cancer (NSCLC) arena, explained Christina Baik, MD,

6January 2021

ASCO Lung Cancer Roundtable – NSCLC – The SINDAS Trial: Addition of SBRT to a Systemic TKI for EGFR

Research, Treatments|

*October 2020*  The GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies

6January 2021

Targeted Radiation Wins for Treating ‘Numerous’ Brain Metastases 

Research, Treatments|

*October 2020* — Similar survival and less cognitive decline compared with conventional WBRT Stereotactic radiosurgery (SRS) for cancer patients with four to 15 brain metastases staved off cognitive decline better than conventional whole-brain radiation therapy (WBRT), while yielding similar

16October 2020

BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models

Research, Treatments|

*September 2020* Additionally, the findings showed that BLU-945 potently and selectively inhibited triple-mutant EGFR, harboring the most common on-target resistance mutations to standard EGFR-targeted therapies, including the third-generation EGFR TKI osimertinib (Tagrisso). Specifically, BLU-945 inhibited triple-mutant EGFR with sub-nanomolar

16October 2020

EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC

Research, Treatments|

*September 2020* The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib (Tagrisso)-resistant patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to findings from the phase 1

16October 2020

First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC

Research, Treatments|

*September 2020* Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival. Read more.

16October 2020

Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer

Research, Treatments|

*September 2020* Nathan A. Pennell, MD, PhD, an associate professor in the Department of Medicine and director of the Lung Cancer Medical Oncology Program at the Taussig Cancer Institute of Cleveland Clinic, discusses the evolution of targeting HER2 in lung cancer. Watch the video.

16October 2020

FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC

Research, Treatments|

*August 2020* The FDA has granted a priority review designation to new drug application (NDA) for tepotinib as a treatment for patient with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor a MET exon 14 (METex14) skipping mutation identified via

16October 2020

FDA Grants Priority Review to Trilaciclib in Chemotherapy-Treated Small Cell Lung Cancer

Research, Treatments|

*August 2020* The FDA has granted Priority Review to the New Drug Application (NDA) for trilaciclib (G1T28) for the treatment of patients with small cell lung cancer (SCLC) who are receiving chemotherapy, G1 Therapeutics announced in a press release.

16October 2020

Radiosurgery Improves Clinical Outcomes in Brain Metastasis Treatment

Research, Treatments|

*August 2020* Joshua Palmer, MD, discusses a pooled analysis of 2 randomized clinical trials that compared how clinical outcomes and quality of life were impacted with stereotactic radiosurgery versus whole-brain radiation therapy in patients with brain metastases. Watch video here.

16October 2020

Homing in on Brain Mets’ Distinct Alterations Offers Hope for Precision Medicine Approach

Research, Treatments|

*August 2020* "Brain metastases harbor distinct clinically actionable genetic alterations compared to their primary tumors and extracranial sites." The use of targeted therapies directed at genetic alterations specific to brain metastases is emerging as a viable precision medicine approach

16October 2020

Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer

Research, Treatments|

*August 2020* Research into mutations in the gene encoding the epidermal growth factor receptor (EGFR) protein has revolutionized non–small cell lung cancer (NSCLC) treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.

18September 2020

Knockdown of IKKβ Inhibits Tumor Development in a Leptomeningeal Metastasis Mouse Model and Proliferation of Lung Cancer Cells

Research, Treatments|

*July 2020* Leptomeningeal metastasis (LM) is a devastating, late-stage complication of various solid tumors and is characterized by the diffuse dissemination of malignant tumor cells into the cerebrospinal fluid (CSF) and leptomeninges. Metastasis to this fluid-filled space can quickly spread

18September 2020

Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series

Research, Treatments|

*July 2020* While individualized oncologic treatments are becoming a common practice, it is necessary to evaluate brain metastases (BM) management in a homogeneous primitive population. In patients with a limited number of BM from NSCLC, SRT is an effective

18September 2020

Treatment Landscape Expands for EGFR-Mutated Non–Small Cell Lung Cancer

Research, Treatments|

*July 2020* In an interview with Targeted Oncology, Balazs Halmos, MD, MS, director of the Multidisciplinary Thoracic Oncology Program and director of the Section of Thoracic Medical Oncology for Montefiore Health Systems, and first director of Clinical Cancer Genetics and professor

18September 2020

Capmatinib Approved in Japan for METex14-Altered Advanced NSCLC

Research, Treatments|

*June 2020* Note: Capmatinib was approved by the FDA in May 2020 for MET exon 14 skipping mutation. The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved capmatinib (Tabrecta; formerly INC280) for patients with MET exon 14 skipping (METex14) mutation–positive advanced and/or

12June 2020

Almonertinib Induces Response in EGFR T790M-Positive NSCLC With CNS Metastases

Research, Treatments|

*May 2020* The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile. Clinical benefit was observed with almonertinib (HS-10296) as treatment of patients with EGFR T790M-mutant non–small

8April 2020

Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research

Research, Treatments|

*March 2020* Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC); however, ongoing research efforts are looking to build upon the benefits with combination strategies and prevent acquired resistance to

8April 2020

Cause of Resistance to 3rd-Gen EGFR-TKIs Varied in T790M-Mutated NSCLC

Research, Treatments|

*March 2020* Targeted sequencing of patients with acquired resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) for EGFR T790M-mutant non-small cell lung cancer (NSCLC) revealed that resistance is associated with diverse pathways. The retrospective study looked at the genomic

8April 2020

FDA Grants Breakthrough Therapy Designation to JNJ-6372 in Metastatic Non-Small Cell Lung Cancer

Research, Treatments|

*March 2020* The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a Johnson & Johnson Company. NJ-6372 is an investigational treatment for metastatic non-small cell lung cancer (mNSCLC) with epidermal growth

8April 2020

Research Aims to Augment OS Benefit With Osimertinib in EGFR+ NSCLC

Research, Treatments|

*March 2020* Osimertinib (Tagrisso) is the standard frontline therapy for patients with metastatic, EGFR-mutant non–small cell lung cancer (NSCLC), and although the drug can provide years of benefit, more options beyond chemotherapy are needed for those who progress on this

1April 2020

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

Research, Treatments|

*January 2020* Among 62 patients who met eligibility critieria, histologic transformation, primarily squamous transformation, was identified in 15% of first-line osimertinib cases and 14% of later-line cases. Nineteen percent (5/27) of patients treated with first-line osimertinib had off-target genetic

4March 2020

Scientists link common immune cell to failure of checkpoint inhibitors in lung cancer

Research, Treatments|

*December 2019* Checkpoint inhibitors come with a huge caveat: They only help a small subset of patients. Doctors struggle to predict who these patients are and—just as important—who they aren't. Results from a new study published Dec. 19 in

4March 2020

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

Research, Treatments|

*January 2020* Oncoprex in combination with osimertinib (Tagrisso) received fast track designation from the FDA to treat patients with non-small cell lung cancer (NSCLC) with EFGR mutations that progressed after treatment with osimertinib alone, according to Genprex, Inc., the immunogene therapy’s

4March 2020

FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC

Research, Treatments|

*January 2020* The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application (sBLA) for intravenous ramucirumab (Cyramza) injection for use in combination with erlotinib (Tarceva)

18January 2020

Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

Research, Treatments|

*December 2019* With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small cell lung cancer (NSCLC), novel options like lazertinib (YH25448), an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib

18January 2020

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC

Research, Treatments|

*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the

18January 2020

Osimertinib promising for EGFR-mutant NSCLC with leptomeningeal metastases

Research, Treatments|

*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest. Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Republic of Korea) and

18January 2020

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

Funding, Research|

*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer. The Chen-Huang Center

20December 2019

Project PRIORITY: Why it matters to the EGFR-positive lung cancer community

Advocacy, Coping With Cancer, Research|

*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR Resisters—a grassroots, patient-driven community dedicated exclusively to changing EGFR-positive lung cancer into a manageable chronic disease. Goal of Project

8November 2019

Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLC

Research, Treatments|

*June 2019*  by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is

25September 2019

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

Research, Treatments|

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often

12August 2019

In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer

Research, Treatments|

*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival.Advances in cancer research have highlighted the importance of understanding the specific characteristics of each person’s cancer. These

12August 2019

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

Research|

*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with advanced cancer. However, not all patients benefit equally from treatment, and confounding immune‐related issues may have an impact. Several

18June 2019

High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients

Research, Treatments|

*January 2019*  Lung Cancer.   This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and resistance to EGFR-TKI medications in patients with treatment-naïve advanced EGFR mutant lung adenocarcinoma. (By treatment naïve, these patients had

17March 2019

Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance

Research, Treatments|

*March 2019*  This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the effectiveness of the afatinib + cetuximab combo treatment especially useful for T790M negative patients who developed acquired resistance to

14March 2019

Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon  

Research, Treatments|

*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for treatment monitoring and minimal residual disease (MRD) assessment. The test is being developed by Natera and is not yet

3February 2019

A cancer researcher reflects on the evolution of lung cancer therapies

Research, Treatments|

*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons.   When Dr. Lecia Sequist was undergoing her training to become a medical oncologist at Massachusetts General Hospital (MGH) in the early 2000s, the treatments available for lung cancer

3February 2019

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC

Research, Treatments|

*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from

5January 2019

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?

Research, Treatments|

*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer. Videos from the live webcast: Newer Technologies in Radiation; Novel Indications for Local Therapy in Advanced NSCLC; Systemic Therapies

22November 2018

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

Research, Treatments|

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived

22November 2018

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Research, Treatments|

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between

18June 2018

Bring Hope Home

Research|

June 19th Living Room "Resistance to Targeted Therapy" Dr. Colin Blakely will be discussing all the questions about progression in your lung cancer and where to go and what to do. Dr. Blakely will be talking about what is happening in the

Donate

Support EGFR

Latest Newsletter

Get Social: Twitter

Categories

Living with EGFR

Supporting Research

Finding Hope

Join Us.

Do you (or a loved one) have EGFR-positive lung cancer? Your voice matters! By participating in this survey, YOU could help shape EGFR-positive lung cancer treatment development and future research, ensuring that they address what is most important to the EGFR-positive lung cancer community.
TAKE SURVEY HERE
Go to Top